Evidence map›Paper›PMID 35453506›Full record

ArticleBiomedicines2022

BRAF

Ophélie Delcorte, Catherine Spourquet, Pascale Lemoine, Jonathan Degosserie, Patrick Van Der Smissen, Nicolas Dauguet, Axelle Loriot, Jeffrey A Knauf, Laurent Gatto, Etienne Marbaix and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. BRAFCancers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Ophélie DelcorteCELL Unit, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.ORCID 0000-0003-1914-7670
Catherine SpourquetCELL Unit, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.ORCID 0000-0002-6799-1879
Pascale LemoineCELL Unit, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
Jonathan DegosserieCELL Unit, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.ORCID 0000-0001-8654-4831
Patrick Van Der SmissenCELL Unit, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
Nicolas DauguetCYTF Platform, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
Axelle LoriotComputational Biology and Bioinformatics, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
Jeffrey A KnaufDepartment of Medicine and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Laurent GattoComputational Biology and Bioinformatics, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.ORCID 0000-0002-1520-2268
Etienne MarbaixCELL Unit, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
James A FaginDepartment of Medicine and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Christophe E PierreuxCELL Unit, de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.ORCID 0000-0002-9647-2816
de Duve Institute · BEMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Papillary thyroid cancer (PTC) is the most common endocrine malignancy for which diagnosis and recurrences still challenge clinicians. New perspectives to overcome these issues could come from the study of extracellular vesicle (EV) populations and content. Here, we aimed to elucidate the heterogeneity of EVs circulating in the tumor and the changes in their microRNA content during cancer progression. Using a mouse model expressing BRAF

Indexed as

BRAFV600Eextracellular vesiclesheterogeneitymiRNAmouse modelPTCsequencingthyroid cancer

Identifiers

PMID35453506
PMCPMC9029139
OpenAlexW4221033208

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.